jeremy-carver-the-international-consortium-on-anti-virals-icav-canada

Jeremy Carver

President and Chief Executive Officer

BA, PhD

Dr. Carver is a serial innovator – the Founding President & CEO of the International Consortium on Anti-Virals (ICAV-CITAV) – 2004 to present – an organization of over 300 scientists from 42 countries on five continents that is dedicated to discovering and delivering low-cost anti-microbial drugs to low and middle income countries

As Founding President, CEO and CSO of the biotech company GlycoDesign Inc (1994 -2002), he grew the company to over 100 employees and listed it on the TSE with a $150M market capitalization. During his prior 26-year academic career Dr Carver published over 200 peer-reviewed papers. As Associate Dean Basic Science he launched a structural biology initiative in partnership with the Hospital Research Institutes that is still a North American powerhouse. He is an Emeritus Professor at the University of Toronto. He was Professor (1968-94) and Associate Dean Basic Science (1989-1992), Faculty of Medicine, University of Toronto. He received a Ph.D. (Biophysics, Harvard University) and an Hons. B.A. (Physics, University of Toronto), a Helen Hay Whitney Postdoctoral Fellowship (Oxford University) and a World Trade Visiting Scientist Award (IBM Watson Labs).

logo-the-international-consortium-on-anti-virals-icav-canada

Contact